Are there any early-phase opportunities left in hepatitis C?
This article was originally published in Scrip
Executive Summary
With Harvoni (sofosbuvir/ledipasvir; Gilead Sciences) and Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir; AbbVie) demonstrating cure rates approaching 100% in several patient subgroups, there is now a very high bar to market entry in the hepatitis C space. Pharmaceutical companies are left trying to provide incremental improvements in treatment duration and broader genotypic potency in order to differentiate newer products.